Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perimenopause alternatives

This article was originally published in The Tan Sheet

Executive Summary

Women attempting to manage the period before menopause should consider vitamin E for hot flashes and vitamin D/calcium for osteoporosis, according to a report in latest Journal of the American Pharmaceutical Association. The review of perimenopause treatments, part of an ongoing women's health series in the journal, notes many women do not get enough vitamin D, which helps the body absorb calcium. Authored by Edyta Frackiewicz and Neal Cutler, California Clinical Trials (Beverly Hills), the review also recommends pharmacists help women choose smoking cessation therapies, since quitting can help alleviate perimenopause symptoms. Phytoestrogen intake through soy also is highlighted, although the authors note supplements may be more attractive than food sources, due to large (45 g/day) recommended intakes

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel